Clinical characteristics and treatment outcomes of neuroblastoma with pulmonary metastases.
5 affiliations
- 1School of Pediatrics, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, People's Republic of China.
- 2Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
- 3Department of Medical Oncology, Pediatric Oncology Centre, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, People's Republic of China.
- 4Department of Radiology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, People's Republic of China.
- 5Department of Surgical Oncology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Beijing, People's Republic of China.
Abstract
Objective
To describe the clinical characteristics, treatment processes, and prognosis of primary neuroblastoma (NB) with concurrent pulmonary metastases.Methods
Clinical data were collected retrospectively from 10 patients with primary NB and concurrent pulmonary metastases in our institution from March 2019 to October 2025. We collected and analyzed clinical and pathological features, imaging characteristics, and therapeutic responses.Results
This cohort comprised seven boys and three girls, with a median age of 45.5 months (range 29-200 months). All patients were classified as stage M and high-risk group. N-myc proto-oncogene (MYCN) amplification was seen in four cases and gain in three cases. Heterogeneous responses to induction chemotherapy were observed. The primary tumor and bone marrow metastases showed favorable responses, whereas pulmonary metastases exhibited low sensitivity to chemotherapy. Nine patients died with a median survival of 17 months (range 5-64 months); one patient survived for 62 months. In the later stages of treatment, tumor progression or recurrence occurred in 9 patients, with bone (n=4), liver (n=4), lung (n=4), primary tumor site (n=3), distant lymph nodes (n=2), brain (n=2), and bone marrow (n=1) being the sites of first progression or recurrence.Conclusions
Primary NB with pulmonary metastases is uncommon, frequently associated with MYCN amplification and multiple non-pulmonary metastases; prognosis is poor. Current clinical management predominantly involves systemic therapy, with limited local interventions for pulmonary metastases. Treatment responses vary across primary tumors and different metastatic sites.
Related
- The Relationship Between Primary Colorectal Cancer Tumour Characteristics and Patient Outcomes Following Surgery for Oligometastatic Pulmonary Metastases: A Single-Centre Retrospective Study.
- Clinical and Demographic Characteristics of Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma: A Single-Center Experience
- COVID-19-associated pulmonary aspergillosis: clinical characteristics, species distribution, environmental fungal contamination, and antifungal susceptibility
- Baseline growth kinetics of pulmonary metastases in head and neck adenoid cystic carcinoma: analysis of correlated clinical and molecular factors
- Primary pulmonary NUT carcinoma: pathological features, clinical diagnosis, treatment, and prognosis — An extended review
BibTeX
@article{wei2026clinical,
title = {{Clinical characteristics and treatment outcomes of neuroblastoma with pulmonary metastases.}},
author = {Qian Wei and Guantong He and Binghao Wu and Xin Li and Jun Liu and Yan Su and Tong Yu and Wei Yang and Shen Yang},
journal = {World journal of pediatric surgery},
year = {2026},
month = oct,
doi = {10.1136/wjps-2026-001262},
url = {https://europepmc.org/article/MED/42948607},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Clinical characteristics and treatment outcomes of neuroblastoma with pulmonary metastases.
AU - Qian Wei
AU - Guantong He
AU - Binghao Wu
AU - Xin Li
AU - Jun Liu
AU - Yan Su
AU - Tong Yu
AU - Wei Yang
AU - Shen Yang
PY - 2026
DA - 2026/10/16
JO - World journal of pediatric surgery
DO - 10.1136/wjps-2026-001262
UR - https://europepmc.org/article/MED/42948607
AB - Objective To describe the clinical characteristics, treatment processes, and prognosis of primary neuroblastoma (NB) with concurrent pulmonary metastases.Methods Clinical data were collected retrospectively from 10 patients with primary NB and concurrent pulmonary metastases in our institution from March 2019 to October 2025. We collected and analyzed clinical and pathological features, imaging characteristics, and therapeutic responses.Results This cohort comprised seven boys and three girls, with a median age of 45.5 months (range 29-200 months). All patients were classified as stage M and high-risk group. N-myc proto-oncogene (MYCN) amplification was seen in four cases and gain in three cases. Heterogeneous responses to induction chemotherapy were observed. The primary tumor and bone marrow metastases showed favorable responses, whereas pulmonary metastases exhibited low sensitivity to chemotherapy. Nine patients died with a median survival of 17 months (range 5-64 months); one patient survived for 62 months. In the later stages of treatment, tumor progression or recurrence occurred in 9 patients, with bone (n=4), liver (n=4), lung (n=4), primary tumor site (n=3), distant lymph nodes (n=2), brain (n=2), and bone marrow (n=1) being the sites of first progression or recurrence.Conclusions Primary NB with pulmonary metastases is uncommon, frequently associated with MYCN amplification and multiple non-pulmonary metastases; prognosis is poor. Current clinical management predominantly involves systemic therapy, with limited local interventions for pulmonary metastases. Treatment responses vary across primary tumors and different metastatic sites.
SN - 2096-6938
SN - 2516-5410
ER -